Navigation Links
Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
Date:6/19/2013

New York, New York (PRWEB) June 19, 2013

As Januvia lawsuit claims involving pancreatitis and pancreatic cancer continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) recently held a meeting to discuss the safety of Januvia and other diabetes drugs known as incretin mimetics. According to a June 12th report from Bloomberg.com, the FDA may seek additional data from the makers of Januvia and similar drugs, following a recent study that indicated the medications could increase risks for pancreatic cancer. One of the options being considered by the agency is a large clinical trial designed to show patterns of adverse events. *

“In light of the possible link between Januvia and pancreatic cancer, we certainly hope that the FDA will order more studies of these drugs,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit evaluations to patients who took the medication and were diagnosed with pancreatic cancer or pancreatitis.

Januvia Lawsuits
Incretin mimetics like Januvia help regulate blood sugar by stimulating insulin production by the pancreas. In 2009, information was added to the drug’s label regarding a potential risk for Januvia pancreatitis, after the FDA became aware of 88 post-marketing cases of acute pancreatitis that occurred in patients taking the drug.** In 2011, a study published in the journal Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis by as much as six-fold. The same study found a possible link between Januvia and pancreatic cancer.***

The FDA’s recent meeting was prompted by data from an unpublished study that drugs like Januvia could cause precancerous changes in the cell of the pancreas, Bloomberg.com said. Just prior to the meeting, the American Diabetes Association called for an independent review of all incretin mimetics to provide clarity to patients and health care providers in light of the recent controversy.****

Court documents indicate that Januvia lawsuits filed on behalf of patients who used the drug and developed pancreatic cancer and pancreatitis are already mounting in courts throughout the country. On July 25, 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will meet to discuss whether or not a multidistrict litigation should be established for all federally-filed claims involving incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Alleged victims of Januvia pancreatitis or pancreatic cancer may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*bloomberg.com/news/2013-06-12/merck-joins-novo-to-reassure-safetynof-diabetes-drugs.html
**fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm; September 25, 2009
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
****diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuit2013.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10850018.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Addition of Januvia Cancer Resource Center
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
6. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
7. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
8. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
9. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
10. New Lawsuit Alleges Teen Molestation by Ex-Deputy
11. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company ... clinical study for its dental gel that shows significant reduction in plaque levels and ... triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine and ...
(Date:1/17/2017)... ... 17, 2017 , ... Lynx Technology Partners (Lynx), ... security companies for consecutive years, today announced the appointment of four members to ... nomination process to a close and positions Lynx for even faster growth in ...
(Date:1/16/2017)... ... January 17, 2017 , ... ... an internationally recognized leader in the fast-casual category, announces a hearty and wholesome ... Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show ... Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade ...
(Date:1/16/2017)... ... 16, 2017 , ... As New York’s fastest growing ophthalmic ... to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ... division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, Southampton, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... PARSIPPANY, N.J. , Jan. 17, 2017 Interpace ... that provides clinically useful molecular diagnostic tests and pathology ... it has received a letter dated January 13, 2017 ... it has regained compliance with the requirement of the ... price of $1.00 per share. The letter ...
(Date:1/17/2017)... Research and Markets has announced the addition of the "The Top ... ... and profiles the leading 200 manufacturers and distributors of molecular diagnostics products ... United States and Europe to ... Profile information for each company in The Top 200 Molecular Diagnostics ...
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
Breaking Medicine Technology: